Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 10/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL3352147 | 1.00 | ENPP2 (0.44) | ENPP2LPAR2ALDH1A1FAAHTSHR | |
| SCHEMBL4804211 | 0.92 | ALDH1A1 (0.50) | ENPP2LPAR2ALDH1A1FAAHEPHX1 | |
| SCHEMBL4801706 | 0.92 | ALDH1A1 (0.50) | ENPP2LPAR2ALDH1A1FAAHEPHX1 | |
| SCHEMBL5572878 | 0.92 | ENPP2 (0.35) | ENPP2LPAR2FAAH | |
| SCHEMBL9807194 | 0.92 | ALDH1A1 (0.50) | ENPP2LPAR2ALDH1A1FAAHEPHX1 | |
| SCHEMBL4801711 | 0.92 | ALDH1A1 (0.50) | ENPP2LPAR2ALDH1A1FAAHEPHX1 | |
| SCHEMBL9807187 | 0.92 | ALDH1A1 (0.50) | ENPP2LPAR2ALDH1A1FAAHEPHX1 | |
| SCHEMBL5575577 | 0.92 | ENPP2 (0.35) | ENPP2LPAR2FAAH | |
| SCHEMBL5575582 | 0.92 | ENPP2 (0.35) | ENPP2LPAR2FAAH | |
| SCHEMBL5572875 | 0.92 | ENPP2 (0.35) | ENPP2LPAR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7531676-B2 | Lipids | CELLTECH R & D LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-20060148761-A1 | Lipids | CELLTECH R & D LIMITED | 2006-07-06 | — | — | US | disclosed |
| US-20040024220-A1 | Lipids | CELLTECH R & D LIMITED | 2004-02-05 | — | — | US | disclosed |
| US-6583301-B1 | Bipolar; form complexes with polyanions; delivering bioactive substances such as nucleic acids to cells in vitro and in vivo | CELLTECH R & D LIMITED (GB) | 2003-06-24 | — | — | US | disclosed |
| EP-1204428-A2 | TARGETED LIPID PARTICLES | Celltech R&D Limited (GB) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001012154-A2 | TARGETED LIPID PARTICLES | CELLTECH R&D LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| EP-1070047-A2 | LIPIDS | Celltech Chiroscience Limited (GB) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052858-A2 | LIPIDS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024220-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | ENPP2 301/4885LPAR2 9/4885ALDH1A1 4222/4885 |
| US-20060148761-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | ENPP2 301/4885LPAR2 9/4885ALDH1A1 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.